Retatrutide, from Soma Pharmaceuticals , is gaining considerable attention as a innovative therapy for obesity control . This innovative compound combines the properties of a GLP-1 receptor stimulant and a GIP receptor stimulant, designed to effectively promote metabolic improvements but also address related metabolic conditions . Preliminary human